Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

被引：27

作者：

Vazquez, Marta ^{[1
]}

Guevara, Natalia ^{[1
]}

Maldonado, Cecilia ^{[1
]}

Guido, Paulo Caceres ^{[2
]}

Schaiquevich, Paula ^{[3
,4
]}

机构：

[1] Univ Republica, Fac Quim, Dept Ciencias Farmaceut, Montevideo, Uruguay

[2] Hosp Pediat JP Garrahan, Unidad Farmacocinet Clin, Farm, Buenos Aires, DF, Argentina

[3] Hosp Pediat JP Garrahan, Med Precis, Buenos Aires, DF, Argentina

[4] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina

来源：

BIOMED RESEARCH INTERNATIONAL | 2020年 / 2020卷

关键词：

SEROTONIN REUPTAKE INHIBITORS; P-GLYCOPROTEIN INHIBITION; BLOOD-BRAIN-BARRIER; VALPROIC ACID; IN-VITRO; NEUROPATHIC PAIN; HUMAN LIVER; CANNABIDIOL; METABOLISM; VENLAFAXINE;

D O I：

10.1155/2020/3902740

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).

引用

页数：9

共 50 条

[1] Drug-drug interactions between antiepileptics and cannabinoids
Miziak, Barbara
Walczak, Aleksandra
Szponar, Jaroslaw
Pluta, Ryszard
Czuczwar, Stanislaw J.
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 407 - 415
[2] Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions
Vazquez, Marta
Garcia-Carnelli, Carlos
Maldonado, Cecilia
Fagiolino, Pietro
[J]. CANNABINOIDS AND SLEEP: MOLECULAR, FUNCTIONAL AND CLINICAL ASPECTS, 2021, 1297 : 27 - 42
[3] Economic implications of potential drug-drug interactions in chronic pain patients
Taylor, Robert, Jr.
Pergolizzi, Joseph V., Jr.
Puenpatom, R. Amy
Summers, Kent H.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (06) : 725 - 734
[4] Incidence of potential drug-drug interactions with antidiabetic drugs
Samardzic, I.
Bacic-Vrca, V.
[J]. PHARMAZIE, 2015, 70 (06): : 410 - 415
[5] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
Paul Hollywood
Rachel MacCann
David Lorigan
Eoghan de Barra
Samuel McConkey
[J]. Irish Journal of Medical Science (1971 -), 2020, 189 : 693 - 699
[6] Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions
Ben D. Snyder
Andrew Rowland
Thomas M. Polasek
John O. Miners
Matthew P. Doogue
[J]. European Journal of Clinical Pharmacology, 2014, 70 : 1115 - 1122
[7] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
Hollywood, Paul
MacCann, Rachel
Lorigan, David
de Barra, Eoghan
McConkey, Samuel
[J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2020, 189 (02) : 693 - 699
[8] Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions
Snyder, Ben D.
Rowland, Andrew
Polasek, Thomas M.
Miners, John O.
Doogue, Matthew P.
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (09) : 1115 - 1122
[9] Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs
Land, M. Hunter
MacNair, Laura
Thomas, Brian F.
Peters, Erica N.
Bonn-Miller, Marcel O.
[J]. CANNABIS AND CANNABINOID RESEARCH, 2020, 5 (04) : 340 - 343
[10] Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy
Bardhi, Keti
Coates, Shelby
Watson, Christy J. W.
Lazarus, Philip
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (12) : 1443 - 1460

← 1 2 3 4 5 →